IL162754A0 - Bilayer pharmaceutical tablet comprising telmisartane and a diuretic and preparation thereof - Google Patents
Bilayer pharmaceutical tablet comprising telmisartane and a diuretic and preparation thereofInfo
- Publication number
- IL162754A0 IL162754A0 IL16275402A IL16275402A IL162754A0 IL 162754 A0 IL162754 A0 IL 162754A0 IL 16275402 A IL16275402 A IL 16275402A IL 16275402 A IL16275402 A IL 16275402A IL 162754 A0 IL162754 A0 IL 162754A0
- Authority
- IL
- Israel
- Prior art keywords
- diuretic
- telmisartane
- preparation
- pharmaceutical tablet
- bilayer pharmaceutical
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/63—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide
- A61K31/635—Compounds containing para-N-benzenesulfonyl-N-groups, e.g. sulfanilamide, p-nitrobenzenesulfonyl hydrazide having a heterocyclic ring, e.g. sulfadiazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Inorganic Insulating Materials (AREA)
- Analysing Materials By The Use Of Radiation (AREA)
- Separation Using Semi-Permeable Membranes (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Lubricants (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Treatment Of Liquids With Adsorbents In General (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2002/000395 WO2003059327A1 (en) | 2002-01-16 | 2002-01-16 | Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
IL162754A0 true IL162754A0 (en) | 2005-11-20 |
Family
ID=8164784
Family Applications (4)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL16275402A IL162754A0 (en) | 2002-01-16 | 2002-01-16 | Bilayer pharmaceutical tablet comprising telmisartane and a diuretic and preparation thereof |
IL162754A IL162754A (en) | 2002-01-16 | 2004-06-28 | Method for producing a bilayer pharmaceutical tablet comprising telmisartan and a diuretic |
IL194933A IL194933A (en) | 2002-01-16 | 2008-10-27 | A method for making amorphous telemicretin |
IL219481A IL219481A (en) | 2002-01-16 | 2012-04-30 | Two-tiered pharmacy tablet for use in the treatment of hypertension containing telmisartan and thiazide as a diuretic |
Family Applications After (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
IL162754A IL162754A (en) | 2002-01-16 | 2004-06-28 | Method for producing a bilayer pharmaceutical tablet comprising telmisartan and a diuretic |
IL194933A IL194933A (en) | 2002-01-16 | 2008-10-27 | A method for making amorphous telemicretin |
IL219481A IL219481A (en) | 2002-01-16 | 2012-04-30 | Two-tiered pharmacy tablet for use in the treatment of hypertension containing telmisartan and thiazide as a diuretic |
Country Status (30)
Country | Link |
---|---|
US (3) | US20050089575A1 (pt) |
EP (3) | EP1854454B1 (pt) |
JP (2) | JP4181503B2 (pt) |
KR (2) | KR100876302B1 (pt) |
CN (2) | CN100571695C (pt) |
AT (1) | ATE380547T1 (pt) |
AU (2) | AU2002242676B2 (pt) |
BG (3) | BG66524B1 (pt) |
BR (1) | BR0215514A (pt) |
CA (2) | CA2651604C (pt) |
CY (3) | CY1107226T1 (pt) |
CZ (1) | CZ303145B6 (pt) |
DE (1) | DE60224096T3 (pt) |
DK (3) | DK1467712T4 (pt) |
EA (2) | EA007614B1 (pt) |
ES (3) | ES2445041T3 (pt) |
HK (1) | HK1073785A1 (pt) |
HR (1) | HRP20040649B1 (pt) |
HU (1) | HU229941B1 (pt) |
IL (4) | IL162754A0 (pt) |
ME (1) | ME02761B (pt) |
MX (1) | MXPA04006997A (pt) |
NO (3) | NO345891B1 (pt) |
NZ (1) | NZ534502A (pt) |
PT (3) | PT1854454E (pt) |
RS (1) | RS52012B (pt) |
SI (1) | SI1467712T2 (pt) |
SK (1) | SK288439B6 (pt) |
UA (1) | UA78273C2 (pt) |
WO (1) | WO2003059327A1 (pt) |
Families Citing this family (108)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE60224096T3 (de) | 2002-01-16 | 2012-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur herstellung einer zweischichtigen pharmazeutischen tablette enthaltend telmisartan und hydrochlorothiazid |
US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
US8980870B2 (en) | 2002-09-24 | 2015-03-17 | Boehringer Ingelheim International Gmbh | Solid telmisartan pharmaceutical formulations |
DE10244681A1 (de) * | 2002-09-24 | 2004-04-08 | Boehringer Ingelheim International Gmbh | Neue feste Telmisartan enthaltende pharmazeutische Formulierungen und deren Herstellung |
WO2004064846A1 (en) | 2003-01-14 | 2004-08-05 | Gilead Sciences, Inc. | Compositions and methods for combination antiviral therapy |
DE10319450A1 (de) * | 2003-04-30 | 2004-11-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Pharmazeutische Formulierung des Telmisartan Natriumsalzes |
US9029363B2 (en) | 2003-04-30 | 2015-05-12 | Boehringer Ingelheim International Gmbh | Telmisartan sodium salt pharmaceutical formulation |
EP1648515B1 (en) * | 2003-07-16 | 2012-11-21 | Boehringer Ingelheim International GmbH | Chlorthalidone combinations |
WO2005082329A2 (en) * | 2004-02-19 | 2005-09-09 | Ranbaxy Laboratories Limited | Process for the preparation of solid dosage forms of valsartan and hydrochlorthiazide |
US20060078615A1 (en) * | 2004-10-12 | 2006-04-13 | Boehringer Ingelheim International Gmbh | Bilayer tablet of telmisartan and simvastatin |
WO2006044648A1 (en) | 2004-10-15 | 2006-04-27 | Teva Pharmaceutical Industries Ltd. | Process for preparing telmisartan |
KR20070072588A (ko) * | 2004-11-03 | 2007-07-04 | 테바 파마슈티컬 인더스트리즈 리미티드 | 텔미사르탄 나트륨의 비정질형 및 다형 |
DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
PT1814527E (pt) * | 2004-11-05 | 2014-01-16 | Boehringer Ingelheim Int | Comprimido de bicamada compreendendo telmisartan e amlodipina |
KR20070097511A (ko) * | 2004-12-17 | 2007-10-04 | 베링거 인겔하임 인터내셔날 게엠베하 | 텔미사르탄 및 하이드로클로로티아지드를 포함하는 배합치료 |
CN100370984C (zh) * | 2005-03-11 | 2008-02-27 | 浙江泰利森药业有限公司 | 替米沙坦分散片及其制备方法 |
TWI471145B (zh) | 2005-06-13 | 2015-02-01 | Bristol Myers Squibb & Gilead Sciences Llc | 單一式藥學劑量型 |
TWI375560B (en) | 2005-06-13 | 2012-11-01 | Gilead Sciences Inc | Composition comprising dry granulated emtricitabine and tenofovir df and method for making the same |
WO2007001067A2 (en) * | 2005-06-27 | 2007-01-04 | Daiichi Sankyo Company, Limited | Solid dosage form comprising an angiotensin ii receptor antagonist and a calcium channel blocker |
GT200600371A (es) * | 2005-08-17 | 2007-03-21 | Formas de dosis sólidas de valsartan y amlodipina y método para hacer las mismas | |
WO2007061415A1 (en) * | 2005-11-22 | 2007-05-31 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical compositions of telmisartan |
US20070116759A1 (en) * | 2005-11-22 | 2007-05-24 | Gershon Kolatkar | Pharmaceutical compositions of telmisartan |
US8637078B2 (en) | 2005-11-24 | 2014-01-28 | Boehringer Ingelheim International Gmbh | Bilayer tablet comprising telmisartan and diuretic |
US20070259930A1 (en) * | 2006-04-10 | 2007-11-08 | Knopp Neurosciences, Inc. | Compositions and methods of using r(+) pramipexole |
US8518926B2 (en) * | 2006-04-10 | 2013-08-27 | Knopp Neurosciences, Inc. | Compositions and methods of using (R)-pramipexole |
EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
NO347644B1 (no) | 2006-05-04 | 2024-02-12 | Boehringer Ingelheim Int | Polymorfer |
EP2497472A1 (en) | 2006-05-16 | 2012-09-12 | Knopp Neurosciences, Inc. | Therapeutically effective amounts of R(+) and S(-) pramipexole for use in the treatment of Parkinson's disease and their pharmaceutical compositions |
CN101448498B (zh) | 2006-05-16 | 2011-04-27 | 诺普神经科学股份有限公司 | R(+)和s(-)普拉克索的组合物以及使用该组合物的方法 |
KR101643626B1 (ko) | 2006-06-01 | 2016-07-29 | 쉐링-플라우 코포레이션, 유.에스.에이. | 결장 흡수용 페닐에프린 약제학적 제형 및 조성물 |
SI2269583T1 (sl) | 2006-06-16 | 2014-12-31 | Lek Pharmaceuticals D.D. | Farmacevtski pripravek, ki vsebuje hidroklorotiazid in telmisartan |
PE20120542A1 (es) * | 2006-06-27 | 2012-05-14 | Novartis Ag | Formas de dosificacion solidas de valsartan, amlodipina e hidroclorotiazida y metodo para elaborarlas |
KR100888131B1 (ko) * | 2006-10-10 | 2009-03-11 | 한올제약주식회사 | 시간차 투약 원리를 이용한 심혈관계 질환 치료용 복합제제 |
CN101534798B (zh) * | 2006-10-30 | 2012-02-15 | 韩诺生物制约株式会社 | 包含噻嗪类和血管紧张素ⅱ受体阻断剂的控释药物组合物 |
US8524695B2 (en) * | 2006-12-14 | 2013-09-03 | Knopp Neurosciences, Inc. | Modified release formulations of (6R)-4,5,6,7-tetrahydro-N6-propyl-2,6-benzothiazole-diamine and methods of using the same |
US8519148B2 (en) * | 2007-03-14 | 2013-08-27 | Knopp Neurosciences, Inc. | Synthesis of chirally purified substituted benzothiazole diamines |
EP1970053A1 (en) * | 2007-03-14 | 2008-09-17 | Boehringer Ingelheim Pharma GmbH & Co. KG | Pharmaceutical composition |
US20080286344A1 (en) * | 2007-05-16 | 2008-11-20 | Olivia Darmuzey | Solid form |
US20090004248A1 (en) * | 2007-06-29 | 2009-01-01 | Frank Bunick | Dual portion dosage lozenge form |
US20100247649A1 (en) * | 2007-10-30 | 2010-09-30 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical formulations comprising telmisartan and hydrochlorothiazide |
RU2482839C2 (ru) | 2007-10-31 | 2013-05-27 | МакНЕЙЛС-ППС, ИНК. | Распадающаяся в полости рта лекарственная форма |
EP2252273B1 (en) | 2008-03-19 | 2016-12-28 | ratiopharm GmbH | Solid pharmaceutical composition comprising a non-peptide angiotensin ii receptor antagonist and a diuretic |
AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
WO2009135646A2 (en) * | 2008-05-05 | 2009-11-12 | Farmaprojects, Sa | Stable pharmaceutical compositions and their processes for preparation suitable for industrial scale |
CZ301070B6 (cs) * | 2008-07-31 | 2009-10-29 | Zentiva, A. S. | Telmisartan tablety |
KR20200118243A (ko) | 2008-08-06 | 2020-10-14 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
WO2010022140A1 (en) * | 2008-08-19 | 2010-02-25 | Knopp Neurosciences, Inc. | Compositions and methods of using (r)-pramipexole |
US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
CZ301299B6 (cs) | 2008-11-24 | 2010-01-06 | Zentiva, A.S. | Pevná farmaceutická kompozice s úcinnými látkami atorvastatinem a telmisartanem |
WO2010075347A2 (en) * | 2008-12-23 | 2010-07-01 | Takeda Pharmaceutical Company Limited | Methods of treating hypertension with at least one angiotensin ii receptor blocker and chlorthalidone |
EP2210595A1 (en) | 2009-01-14 | 2010-07-28 | LEK Pharmaceuticals d.d. | Active coating of pharmaceutical dosage forms |
CN102438598B (zh) * | 2009-05-27 | 2015-06-10 | 株式会社茶山医化 | 含有泡腾层的多层片 |
JP2012529431A (ja) * | 2009-06-08 | 2012-11-22 | メルク・シャープ・アンド・ドーム・コーポレーション | トロンビン受容体アンタゴニストおよびクロピドグレルの固定用量錠剤 |
PL2443094T3 (pl) | 2009-06-19 | 2013-08-30 | Krka Tovarna Zdravil D D Novo Mesto | Sposób wytwarzania telmisartanu |
WO2010148409A1 (en) * | 2009-06-19 | 2010-12-23 | Knopp Neurosciences, Inc. | Compositions and methods for treating amyotrophic lateral sclerosis |
EP2442794A1 (en) * | 2009-06-19 | 2012-04-25 | Nanoform Hungary Ltd. | Nanoparticulate telmisartan compositions and process for the preparation thereof |
EP2448575A2 (en) | 2009-07-02 | 2012-05-09 | Bilgic Mahmut | Pharmaceutical composition increasing solubility and stability |
TR200906506A2 (tr) | 2009-08-24 | 2011-03-21 | Bi̇lgi̇ç Mahmut | Telmisartan içeren katı dozaj formları. |
CN101632678B (zh) * | 2009-09-01 | 2011-09-14 | 严洁 | 一种氯沙坦钾氢***组合物及其制备方法 |
US9610224B2 (en) | 2009-09-24 | 2017-04-04 | Johnson & Johnson Consumer Inc. | Manufacture of tablet in a die utilizing powder blend containing water-containing material |
US8858210B2 (en) | 2009-09-24 | 2014-10-14 | Mcneil-Ppc, Inc. | Manufacture of variable density dosage forms utilizing radiofrequency energy |
EA034869B1 (ru) | 2009-11-27 | 2020-03-31 | Бёрингер Ингельхайм Интернациональ Гмбх | Лечение генотипированных пациентов с диабетом ингибиторами дпп-4, такими как линаглиптин |
KR101010325B1 (ko) * | 2009-12-17 | 2011-01-25 | 현대약품 주식회사 | 텔미사르탄 및 히드로클로로티아지드를 함유하는 약제학적 조성물 |
EP2377521A1 (en) | 2010-03-26 | 2011-10-19 | Abdi Ibrahim Ilac Sanayi ve Ticaret Anonim Sirketi | Pharmaceutical formulations of telmisartan and diuretic combination |
MX341025B (es) | 2010-05-05 | 2016-08-04 | Boehringer Ingelheim Int Gmbh * | Terapia de combinacion. |
KR101248804B1 (ko) * | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | HMG-CoA 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
WO2011161123A2 (en) | 2010-06-21 | 2011-12-29 | Krka, Tovarna Zdravil, D.D., Novo Mesto | Multilayer pharmaceutical tablet comprising telmisartan and a diuretic |
AU2011306064B2 (en) * | 2010-09-22 | 2015-03-12 | Mcneil-Ppc, Inc | Manufacture of variable density dosage forms utilizing radiofrequency energy |
US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
CN102552161B (zh) * | 2010-12-28 | 2016-06-22 | 上海中西制药有限公司 | 一种药物固体制剂的制备方法及所得药物固体制剂 |
GB201116993D0 (en) | 2011-10-03 | 2011-11-16 | Ems Sa | Pharmaceutical compositions of antihypertensives |
WO2013096816A1 (en) | 2011-12-22 | 2013-06-27 | Biogen Idec Ma Inc. | Improved synthesis of amine substituted 4,5,6,7-tetrahydrobenzothiazole compounds |
EP2612658A1 (en) | 2012-01-05 | 2013-07-10 | Laboratorios Lesvi, S.L. | Pharmaceutical compositions of 4'-[(1,4'dimethyl-2'-propyl[2,6'-bi-1h-benzimidazol]-1'-yl)methyl]-[1,1'-biphenyl]-2-carboxylic acid and is 6-chloro-3,4-dihydro-2h-1,2,4-benzothiadiazine-7-sulfonamide-1,1-dioxide |
AU2013213317B2 (en) * | 2012-01-23 | 2016-06-30 | Sun Pharmaceutical Industries Limited | In-situ multilayered tablet technology |
US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
CN102885789A (zh) * | 2012-04-05 | 2013-01-23 | 常州制药厂有限公司 | 一种治疗高血压的复方制剂的制备方法 |
US9511028B2 (en) | 2012-05-01 | 2016-12-06 | Johnson & Johnson Consumer Inc. | Orally disintegrating tablet |
US9445971B2 (en) | 2012-05-01 | 2016-09-20 | Johnson & Johnson Consumer Inc. | Method of manufacturing solid dosage form |
WO2013171167A1 (en) | 2012-05-14 | 2013-11-21 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome |
WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
KR101414873B1 (ko) * | 2012-06-28 | 2014-07-03 | 보령제약 주식회사 | 피마살탄 및 히드로클로로티아지드가 함유된 약제학적 조성물 |
BR102012020648A2 (pt) * | 2012-08-17 | 2014-12-09 | Hypermarcas S A | Preparação farmacêutica oral sólida para a prevenção de doença cardio e cerebrovasculares e comprimido |
CN103040817A (zh) * | 2013-01-08 | 2013-04-17 | 施慧达药业集团(吉林)有限公司 | 一种用于治疗高血压的复方制剂 |
EP2952196A4 (en) | 2013-01-31 | 2016-08-03 | Sawai Seiyaku Kk | MULTILAYER TABLET CONTAINING TELMISARTAN AND HYDROCHLOROTHIAZIDE |
US9662313B2 (en) | 2013-02-28 | 2017-05-30 | Knopp Biosciences Llc | Compositions and methods for treating amyotrophic lateral sclerosis in responders |
LT3019167T (lt) | 2013-07-12 | 2021-03-25 | Knopp Biosciences Llc | Eozinofilų ir (arba) bazofilų padidintų kiekių gydymas |
US9468630B2 (en) | 2013-07-12 | 2016-10-18 | Knopp Biosciences Llc | Compositions and methods for treating conditions related to increased eosinophils |
CA2921381A1 (en) | 2013-08-13 | 2015-02-19 | Knopp Biosciences Llc | Compositions and methods for treating chronic urticaria |
EP3038467B1 (en) | 2013-08-13 | 2020-07-29 | Knopp Biosciences LLC | Compositions and methods for treating plasma cell disorders and b-cell prolymphocytic disorders |
EP3091966B1 (en) | 2014-01-10 | 2019-07-31 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
US9526728B2 (en) | 2014-02-28 | 2016-12-27 | Boehringer Ingelheim International Gmbh | Medical use of a DPP-4 inhibitor |
JP5871294B1 (ja) * | 2015-02-27 | 2016-03-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 即時放出経口錠剤 |
KR20170001921A (ko) | 2015-06-26 | 2017-01-05 | 대원제약주식회사 | 안정성이 개선된 텔미사르탄을 함유하는 약제학적 조성물 및 이의 제조방법 |
KR20170012703A (ko) | 2015-07-22 | 2017-02-03 | 대원제약주식회사 | 텔미사르탄을 함유하는 약제학적 조성물 및 이의 제조방법 |
JP6411662B2 (ja) * | 2016-05-30 | 2018-10-24 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 固定容量配合剤 |
CN109310697A (zh) | 2016-06-10 | 2019-02-05 | 勃林格殷格翰国际有限公司 | 利格列汀和二甲双胍的组合 |
WO2018030559A1 (ko) * | 2016-08-11 | 2018-02-15 | 주식회사 인트로팜텍 | 텔미사르탄을 포함하는 단층정 복합 제제 |
KR101910902B1 (ko) * | 2016-11-03 | 2018-10-24 | 한미약품 주식회사 | 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제 |
CN106749037B (zh) * | 2016-12-21 | 2019-06-21 | 山东大学 | 一种无定型的替米沙坦-戊二酸共晶及其制备方法和应用 |
CN106749036B (zh) * | 2016-12-21 | 2019-06-21 | 山东大学 | 一种无定型的替米沙坦-庚二酸共晶及其制备方法和应用 |
US10493026B2 (en) | 2017-03-20 | 2019-12-03 | Johnson & Johnson Consumer Inc. | Process for making tablet using radiofrequency and lossy coated particles |
KR20200014049A (ko) | 2018-07-31 | 2020-02-10 | 일동제약(주) | 보관 안정성이 확보된 고혈압 및 고지혈증 치료용 복합 조성물 |
CN110934848B (zh) * | 2019-12-20 | 2022-02-15 | 江西杏林白马药业股份有限公司 | 一种替米沙坦胶囊及其制备方法 |
CN112263555B (zh) * | 2020-10-30 | 2023-03-24 | 重庆康刻尔制药股份有限公司 | 一种替米沙坦口崩片及其制备方法 |
US11878022B2 (en) * | 2020-12-10 | 2024-01-23 | Novitium Pharma LLC | Hydrochlorothiazide compositions |
EP4373474A1 (en) | 2021-07-22 | 2024-05-29 | KRKA, D.D., Novo Mesto | Bilayer tablet comprising telmisartan and indapamide |
EP4295839A1 (en) | 2022-06-20 | 2023-12-27 | KRKA, d.d., Novo mesto | Combination of valsartan and indapamide |
Family Cites Families (16)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3025292A (en) * | 1962-03-13 | Reduction of i | ||
US3163645A (en) † | 1964-09-25 | 1964-12-29 | Ciba Geigy Corp | Derivatives of 3, 4-dihydro-2-h-[1, 2, 4]-benzothiadiazine-1, 1-dioxides |
SI9210098B (sl) † | 1991-02-06 | 2000-06-30 | Dr. Karl Thomae | Benzimidazoli, zdravila, ki te spojine vsebujejo, in postopek za njihovo pripravo |
US5464854A (en) * | 1993-11-11 | 1995-11-07 | Depadova; Anathony S. | Method of modifying ovarian hormone-regulated AT1 receptor activity as treatment of incapacitating symptom(s) of P.M.S. |
DE19539574A1 (de) * | 1995-10-25 | 1997-04-30 | Boehringer Mannheim Gmbh | Zubereitungen und Verfahren zur Stabilisierung biologischer Materialien mittels Trocknungsverfahren ohne Einfrieren |
US6087386A (en) * | 1996-06-24 | 2000-07-11 | Merck & Co., Inc. | Composition of enalapril and losartan |
EP0913177A1 (de) * | 1997-11-03 | 1999-05-06 | Roche Diagnostics GmbH | Verfahren zur Herstellung trockener, amorpher Produkte enthaltend biologisch aktive Materialien mittels Konvektionstrocknung, insbesondere Sprühtrocknung |
US6413541B1 (en) * | 1999-01-13 | 2002-07-02 | Dainippon Pharmaceutical Co., Ltd. | Disintegrating tablet in oral cavity and production thereof |
US6235311B1 (en) * | 1998-03-18 | 2001-05-22 | Bristol-Myers Squibb Company | Pharmaceutical composition containing a combination of a statin and aspirin and method |
WO2000027397A1 (en) * | 1998-11-06 | 2000-05-18 | Glaxo Group Limited | Antihypertensive medicaments containing lacidipine and telmisartan |
AU1157500A (en) * | 1998-11-06 | 2000-05-29 | Boehringer Ingelheim International Gmbh | Medicaments based on combinations of lacidipine and telmisartan or of physiological derivatives thereof |
US6358986B1 (en) † | 1999-01-19 | 2002-03-19 | Boehringer Ingelheim Pharma Kg | Polymorphs of telmisartan |
DE19901921C2 (de) * | 1999-01-19 | 2001-01-04 | Boehringer Ingelheim Pharma | Polymorphe von Telmisartan, Verfahren zu deren Herstellung und deren Verwendung zur Herstellung eines Arzneimittels |
US6576256B2 (en) * | 2001-08-28 | 2003-06-10 | The Brigham And Women's Hospital, Inc. | Treatment of patients at elevated cardiovascular risk with a combination of a cholesterol-lowering agent, an inhibitor of the renin-angiotensin system, and aspirin |
US6737432B2 (en) * | 2001-10-31 | 2004-05-18 | Boehringer Ingelheim Pharma Kg | Crystalline form of telmisartan sodium |
DE60224096T3 (de) | 2002-01-16 | 2012-01-12 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur herstellung einer zweischichtigen pharmazeutischen tablette enthaltend telmisartan und hydrochlorothiazid |
-
2002
- 2002-01-16 DE DE60224096T patent/DE60224096T3/de not_active Expired - Lifetime
- 2002-01-16 JP JP2003559490A patent/JP4181503B2/ja not_active Expired - Lifetime
- 2002-01-16 CN CNB028271823A patent/CN100571695C/zh not_active Expired - Lifetime
- 2002-01-16 ES ES07115060.1T patent/ES2445041T3/es not_active Expired - Lifetime
- 2002-01-16 EP EP07115060.1A patent/EP1854454B1/en not_active Expired - Lifetime
- 2002-01-16 ES ES02708290T patent/ES2298351T5/es not_active Expired - Lifetime
- 2002-01-16 WO PCT/EP2002/000395 patent/WO2003059327A1/en active Application Filing
- 2002-01-16 PT PT71150601T patent/PT1854454E/pt unknown
- 2002-01-16 PT PT101791424T patent/PT2260833E/pt unknown
- 2002-01-16 SI SI200230664T patent/SI1467712T2/sl unknown
- 2002-01-16 CA CA2651604A patent/CA2651604C/en not_active Expired - Fee Related
- 2002-01-16 BR BR0215514-1A patent/BR0215514A/pt active Pending
- 2002-01-16 DK DK02708290.8T patent/DK1467712T4/da active
- 2002-01-16 ES ES10179142T patent/ES2400138T3/es not_active Expired - Lifetime
- 2002-01-16 IL IL16275402A patent/IL162754A0/xx unknown
- 2002-01-16 UA UA20040806794A patent/UA78273C2/uk unknown
- 2002-01-16 PT PT02708290T patent/PT1467712E/pt unknown
- 2002-01-16 CZ CZ20040939A patent/CZ303145B6/cs not_active IP Right Cessation
- 2002-01-16 NO NO20171988A patent/NO345891B1/no not_active IP Right Cessation
- 2002-01-16 EP EP10179142A patent/EP2260833B1/en not_active Expired - Lifetime
- 2002-01-16 SK SK290-2004A patent/SK288439B6/sk not_active IP Right Cessation
- 2002-01-16 RS YU61104A patent/RS52012B/en unknown
- 2002-01-16 KR KR1020087003317A patent/KR100876302B1/ko active IP Right Review Request
- 2002-01-16 DK DK10179142.4T patent/DK2260833T3/da active
- 2002-01-16 MX MXPA04006997A patent/MXPA04006997A/es active IP Right Grant
- 2002-01-16 NZ NZ534502A patent/NZ534502A/en not_active IP Right Cessation
- 2002-01-16 EA EA200400879A patent/EA007614B1/ru not_active IP Right Cessation
- 2002-01-16 DK DK07115060.1T patent/DK1854454T3/da active
- 2002-01-16 KR KR1020047011113A patent/KR100851770B1/ko active IP Right Grant
- 2002-01-16 CA CA002472392A patent/CA2472392C/en not_active Expired - Fee Related
- 2002-01-16 AT AT02708290T patent/ATE380547T1/de active
- 2002-01-16 EA EA200601917A patent/EA012329B1/ru not_active IP Right Cessation
- 2002-01-16 CN CNA2008102144454A patent/CN101352421A/zh active Pending
- 2002-01-16 ME MEP-2008-424A patent/ME02761B/me unknown
- 2002-01-16 HU HU0501086A patent/HU229941B1/hu unknown
- 2002-01-16 AU AU2002242676A patent/AU2002242676B2/en not_active Expired
- 2002-01-16 EP EP02708290A patent/EP1467712B2/en not_active Expired - Lifetime
-
2004
- 2004-06-28 IL IL162754A patent/IL162754A/en active IP Right Grant
- 2004-06-30 BG BG108781A patent/BG66524B1/bg unknown
- 2004-07-15 US US10/892,425 patent/US20050089575A1/en not_active Abandoned
- 2004-07-15 HR HR20040649 patent/HRP20040649B1/xx not_active IP Right Cessation
- 2004-08-11 NO NO20043344A patent/NO342634B1/no not_active IP Right Cessation
-
2005
- 2005-07-27 HK HK05106429.3A patent/HK1073785A1/xx not_active IP Right Cessation
-
2008
- 2008-03-04 CY CY20081100247T patent/CY1107226T1/el unknown
- 2008-07-10 JP JP2008180150A patent/JP4929241B2/ja not_active Expired - Lifetime
- 2008-07-17 AU AU2008203182A patent/AU2008203182B2/en not_active Expired
- 2008-10-27 IL IL194933A patent/IL194933A/en active IP Right Grant
-
2009
- 2009-05-13 US US12/464,957 patent/US20090227802A1/en not_active Abandoned
-
2012
- 2012-04-30 IL IL219481A patent/IL219481A/en not_active IP Right Cessation
-
2013
- 2013-02-15 CY CY20131100140T patent/CY1114929T1/el unknown
- 2013-07-22 US US13/947,429 patent/US20130309307A1/en not_active Abandoned
-
2014
- 2014-01-24 CY CY20141100062T patent/CY1114890T1/el unknown
- 2014-06-27 NO NO20140821A patent/NO336167B1/no not_active IP Right Cessation
-
2015
- 2015-11-19 BG BG112153A patent/BG66588B1/bg unknown
-
2016
- 2016-02-25 BG BG112220A patent/BG67075B1/bg unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1073785A1 (en) | Bilayer pharmaceutical tablet comprising telmisartan and a diuretic and preparation thereof | |
NO20063997L (no) | Tablett med flere lag | |
MY150758A (en) | Bilayer tablet comprising telmisartan and amlodipine | |
LTPA2022524I1 (pt) | ||
TW200628174A (en) | Bilayer tablet | |
EA201001312A1 (ru) | Твердая фармацевтическая композиция, содержащая непептидный антагонист рецептора ангиотензина ii и диуретик | |
AR043395A1 (es) | Terapia de combinacion para la hipertension utilizando lercanidipina y un bloqueante de los receptores de angiotensina ii | |
TH79790B (th) | ยาเม็ดชนิดสองชั้น | |
TH79790A (th) | ยาเม็ดชนิดสองชั้น | |
WO2003080118A3 (en) | Combination of an aldosterone receptor antagonist and a fibric acid derivative | |
TH83710B (th) | การบำบัดรวม |